Hormone therapy study could unlock secrets of immune differences
NCT ID NCT07358897
First seen Feb 01, 2026
Summary
This study will follow 500 transgender adults starting gender-affirming hormone therapy to see how their immune systems change. By tracking immune cells and blood markers before and during treatment, researchers hope to understand why men and women have different rates of autoimmune diseases and infections. The goal is to learn how sex hormones alone—without the influence of chromosomes—shape immune function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSGENDER are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gender-affirming hormone therapy (estrogen or testosterone)
What this could lead to
If successful, this study could reveal how sex hormones influence immune system differences, potentially guiding new treatments for autoimmune diseases and infections.
What could go wrong
This is an observational study that does not test a treatment, so it won't directly lead to new therapies. Results may not apply to non-transgender populations.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.